Investing.com - Eliem Therapeutics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Eliem Therapeutics announced earnings per share of $-0.37 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.43 on revenue of $0.
Eliem Therapeutics 's are down 89% and is trading at $2.83 , still down 85.56% from its 52 week high of $19.60 set on Wednesday, November 17, 2021.
Eliem Therapeutics shares lost 1.05% to trade at $2.83 in intra-day trade the report.
Eliem Therapeutics follows other major Healthcare sector earnings this month
Eliem Therapeutics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar